Treatment of chronic leg ulcers with topical activated XXXX .

@entity1 @entity32 @entity295 @entity3790 @entity563 @entity4537
BACKGROUND: The treatment of @entity4537 frequently presents a management challenge. Nonhealing wounds with poor response to conventional wound management therapy represent a significant cause of disability, affecting approximately 1% of the global population. Activated @entity3790 is a @entity563 protease with anticoagulant, angiogenic, and anti-inflammatory properties that has shown efficacy in @entity1 for the treatment of severe @entity295 . We report 4 cases of nonhealing @entity4537 that were treated with activated @entity3790 . OBSERVATIONS: The study included 4 @entity1 whose wounds were not improving despite standard wound treatment for 4 months or more. Activated @entity3790 was applied topically to their wounds once weekly for 4 weeks. All 4 @entity1 showed a rapid positive response to treatment that was maintained during a 4-month follow-up period. The treatment was well tolerated, with no remarkable adverse effects or complications. CONCLUSIONS: Activated @entity3790 can stimulate wound healing in @entity1 with @entity4537 that are refractory to conventional wound-healing therapies. The likely mechanism of action is its recognized ability to stimulate angiogenesis and reepithelialization and to inhibit @entity32 . Activated @entity3790 has potential as a therapeutic option for @entity1 with @entity4537 .
